Renalytix (LON:RENX) Trading Down 5.9% – What’s Next?

Renalytix Plc (LON:RENX) traded down 5.9% during mid-day trading on Thursday . The stock traded as low as GBX 1.70 and last traded at GBX 1.84. 4,189,669 shares traded hands during mid-day trading, an increase of 288% from the average session volume of 1,080,198 shares. The stock had previously closed at GBX 1.95.

Renalytix Stock Down 2.4%

The firm’s 50 day moving average price is GBX 2.70 and its 200-day moving average price is GBX 5.32. The company has a market cap of £7.89 million, a P/E ratio of -0.45 and a beta of 1.97. The company has a current ratio of 1.21, a quick ratio of 2.42 and a debt-to-equity ratio of -118.57.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).